Provisions for Drug Advertisement Examination

作者:法律资料网 时间:2024-07-04 10:13:58   浏览:9422   来源:法律资料网
下载地址: 点击此处下载

Provisions for Drug Advertisement Examination

State Food and Drug Administration,State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.


下载地址: 点击此处下载

四川省鼓励外商投资的若干规定

四川省人民政府


四川省鼓励外商投资的若干规定
四川省人民政府



第一条 为了进上步改善投资环境,吸收外商投资,引进先进技术,提高产品质量,扩大出口创汇,加速四川省的经济发展,根据国务院《关于鼓励外商投资的规定》,结合我省实际,特制订本规定。
第二条 产品出口企业和先进技术企业,经营期在十年以上的,经企业申请,税务机关批准,从开始获利第一年起至第四年,免征地方所得税;第五年至第八年,减半征收地方所得税。
第三条 按照本规定第二条免征地方所得税期满后,当年出口值占当年产值百分之六十以上的产品出口企业,继续免征地方所得税。
第四条 产品出口企业和先进技术企业,从投产年度起算,第一年至第三年免征房产税和车船使用牌照税,第四年到第八年减半征收房产税和车船使用牌照税。
非产品出口和先进技术的外商投资企业从投产或营业年度起算,第一年至第三年免征房产税和车船使用牌照税。
凡兴办在凉山、阿坝、甘孜和四川省其它待开发地区的外商投资企业,在以上减免征收房产税和车船使用牌照税期满后,继续减半征收房产税和车船使用牌照税至第十年为止。
第五条 经营期在十年以上的产品出口企业和先进技术企业,除成都市市区繁华地段以外,从企业设立之年起算,免收场地使用费三年,从第四年起,按国家规定的场地使用费计收标准下限的百分之五十计收场地使用费三年;在以上减免场地使用费期满后,凡当年出口值占当年产值百
分之六十以上的,由企业申请,经省政府或其受托机构批准,可按国家规定的场地使用费计收标准下限的百分之五十计收场地使用费。
非产品出口和先进技术的外商投资企业,除成都市市区的繁华地段以外,从设立之年起,场地使用费每年按每平方米五至十五元的标准计收,但另有规定的除外。
在农业、畜牧业、养殖业或在凉山、阿坝、甘孜和四川省其他待开发地区,外商投资企业的场地使用费参照前款规定从优从低计收。
各市、地、州不得在国家和省统一规定的场地使用费计收标准以外附加任何其他费用。
第六条 对产品出口企业和先进技术企业,优先提供资源资料、运输条件和通讯设施;生产经营所需水、电、气、国内统配物资,由各级计划部门纳入计划优先供应,并按国营企业的收费标准计收费用。
第七条 产品出口企业和先进技术企业在生产和流通过程中需借贷的短期周转资金或其他必需的信贷资金,由中国银行成都分行或经中国人民银行四川省分行指定的其他金融机构审核后优先贷放;非产品出口企业为履行企业合同或出口合同所需的短期周转资金,经上述银行或金融机构
审核同意亦可优先贷放。
第八条 在外汇管理部门的监管下,外商投资企业之间互相调剂外汇余缺后,不能保证外汇收支平衡的先进技术企业进口原材料或外商汇出应分利润所需的外汇,除通过上述调剂办法外,可经有批准权的对外经济贸易部门批准后,用企业所获利润的人民币部门购买计划外商品出口,仍
有困难时,由省统筹调剂解决。
第九条 鼓励外国投资者来川直接参加企业的经营管理。外籍管理人员和职员凭企业主管部门的证明文件,在四川省境内的旅行食宿,以及购买生活必需品的价格标准,同中国公民同等对待。
第十条 对来川投资的国外企业界人士,我省有关部门可提供有关中国法律、经济、技术金融、劳务等方面的咨询服务。
第十一条 凡四川省审批的项目,其项目建议书的批准或不批准,在收到文件之日起四十天内答复;其可靠性研究报告、企业合同、章程的批准或不批准,在收到文件之日起三十天内答复;其营业执照的申领文件在十天内核转。凡需由国家有关部门审批的,省有关部门在收到全部文件
材料以后,十五天内决定转报或不转报。
第十二条 香港、澳门、台湾的公司、企业其他经济组织,或者个人以及海外华侨投资兴办的企业,除另有规定者外,可参照本规定执行。
第十三条 重庆市可以根据本市情况,制定鼓励外商投资的规定。
第十四条 本规定的解释权属四川省对外经济贸易厅。
第十五条 本规定从发布之日起实施。



1986年12月23日

民政部关于坚决制止在拥军优属活动和召开优抚对象先进代表会议等方面铺张浪费的通知

民政部


民政部关于坚决制止在拥军优属活动和召开优抚对象先进代表会议等方面铺张浪费的通知
民政部


各省、市、自治区民政局:
近来,有些省、自治区民政局在询问一九八○年新年、春节期间如何安排拥军优属活动的同时,也谈了他们准备继续沿用过去动用大量优抚事业费及早采购、印制各种慰问品、纪念品的打算。联系过去几年一些地方在这方面追求形式,不讲实效,大肆铺张浪费的现象,有些问题需要提
请各地注意。例如有些地方在拥军优属活动中,大量印发年画、挂历;赠送纪念册、针线包、元珠笔、钢笔和精制的工艺美术品;借机购买大批高级香烟、茶叶;长期包用影剧院,乱发影戏票;互寄慰问品、纪念品的样品,比排场,讲阔气;大摆宴席请客吃饭,等等。就某些省来说,一次
拥军优属活动要花几十万,甚至数百万元之多。
有些地方,在召开优抚对象先进代表会议时,也出现了不少铺张浪费现象。如:过多地安排文娱活动和游览参观;赠发高级纪念品和奖品;超过标准的多次加餐,增加大会服务人员等等,致使会议费大大超支。
另外,有些省、自治区已经或正在酝酿组织老红军参观团,到北京、西安、延安、遵义、南昌、长沙、广州、武汉等大城市或沿当年红军长征路线游览参观,实际上其中有不少人并非老红军,有些则是在职干部,一花就是几十万甚至上百万元。
上述种种铺张浪费现象,主要是林彪“四人帮”的流毒和影响,是败坏党的艰苦奋斗作风的一种表现,这股不正之风,虽经多次制止,但有些地方仍然置若罔闻。优抚事业费主要应当用于对优抚对象的抚恤和生活补助上,切实解决他们的各种实际困难,体现党和政府对他们的关怀。在
当前优抚事业费有限,优扶对象困难较多的情况下,更要把有限的经费真正用于刀刃上,多做“雪里送炭”,不要搞“锦上添花”,更不应该置烈军属、残废军人、复员退伍军人的实际困难而不顾,任意挥霍浪费。各地必须坚决刹住这股歪风。为此,特提出如下几点意见,望各地认真贯彻
执行。
一、拥军优属活动,必须坚决贯彻节约的原则:
(一)不要再印年画、挂历,采购或精制日用品、工艺品;慰问信可在当地报纸上刊登;烈属和革命残废军人没挂光荣牌的可送光荣牌;
(二)除对部队伤病员,在每人三元以内送些慰问品外,对部队指战员一概不送慰问品,到部队慰问时不要在部队吃饭;
(三)举行军民联欢、座谈会,可演一次电影或一场戏,不招待烟茶,严禁大吃大喝,大摆宴席。
二、今后各级召开优抚对象先进代表会议时,要严格按照财务制度开支各项费用;要尽量减少文娱和游览参观次数;要严格控制大会服务人员人数。对代表一般可发纪念章、奖状,先进集体可发奖旗,必要的可发一点纪念品或奖品。
三、今后不要再组织老红军到外地参观游览。
坚决制止铺张浪费的不正之风,管好、用好优抚事业费,关键在于各级民政部门的领导同志,为了引起各级民政部门对这个问题的重视,请你们把此通知转发到县、市、市辖区民政部门,并广泛宣传在拥军优属活动中必须励行节约,反对铺张浪费的重大意义,严格按照有关规定用好优
扶事业费,使之发挥更大的作用。



1979年10月10日